Joseph E. Bugaj - Concepedia

Author

Joseph E. Bugaj

Also Known As

J Bugaj, J E Bugaj, J. Bugaj, J. E. Bugaj, J.E. Bugaj, JOSEPH BUGAJ, JOSEPH E. BUGAJ, Joseph Bugaj, Joseph E Bugaj, Joseph E. Bugaj

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Mallinckrodt (United States)Mallinckrodt (Ireland)Medibeacon (United States)

About

Joseph E. Bugaj is an author at Mallinckrodt (United States) specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	488
2	Engineering	3	3	366
3	Natural Sciences	2	2	121
4	Biochemistry	2	2	121
5	Health Sciences	1	1	10

Joseph E. Bugaj

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Novel Receptor-Targeted Fluorescent Contrast Agents for In Vivo Tumor Imaging Samuel Achilefu, Richard B. Dorshow, Joseph E. Bugaj, Investigative Radiology	2000	312
Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform Joseph E. Bugaj, Samuel Achilefu, Richard B. Dorshow, Journal of Biomedical Optics EngineeringOncologic ImagingImaging AgentPeptide EngineeringBiomedical Engineering	2001	166
Synthesis, In Vitro Receptor Binding, and In Vivo Evaluation of Fluorescein and Carbocyanine Peptide-Based Optical Contrast Agents Samuel Achilefu, Hermo N. Jimenez, Richard B. Dorshow, Journal of Medicinal Chemistry EngineeringImaging AgentVitro Receptor BindingSomatostatin CompoundsBombesin Peptides	2002	129
Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. Wouter A.P. Breeman, Marion de Jong, Jack L. Erion, PubMed	2002	90
Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo Jean Claude Reubi, Beatrice Waser, Jean‐Claude Schaer, European Journal of Nuclear Medicine and Molecular Imaging Signal TransductionNovel TherapyFunctional SelectivityMedicineDota-cck Analogs	1998	84
DOTA−<scp>d</scp>-Tyr<sup>1</sup>-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy Wen Ping Li, Jason S. Lewis, Joon‐Young Kim, Bioconjugate Chemistry EngineeringChemical BiologyRat ModelTumor BiologyMedicinal Chemistry	2002	71
Stabilization of the Optical Tracer Agent Indocyanine Green Using Noncovalent Interactions Raghavan Rajagopalan, Pamela Uetrecht, Joseph E. Bugaj, Photochemistry and Photobiology Bolus InjectionPharmaceutical ScienceGreen ChemistrySynthetic PhotochemistryChemistry	2000	65
Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model Jason S. Lewis, Mu Wang, Richard Laforest, International Journal of Cancer	2001	60
Novel Bioactive and Stable Neurotensin Peptide Analogues Capable of Delivering Radiopharmaceuticals and Molecular Beacons to Tumors Samuel Achilefu, Ananthacari Srinivasan, Michelle Schmidt, Journal of Medicinal Chemistry Neurotensin ReceptorPeptide ScienceChemical BiologyTumor BiologyMolecular Beacons	2003	56
18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer Eliot T. McKinley, Joseph E. Bugaj, Ping Zhao, Clinical Cancer Research	2011	51

Page 1